Search Videos and More
Course
CME: Early Detection and Interception of Cancer
Through this course we will provide a comprehensive review of current cancer screening guidelines, provide guidance regarding high-risk populations and their management, educate regarding emerging technologies for early cancer detection, and provide referral pathways for complex patients.
News
Dana-Farber Research News 05.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 through April 30.
News
Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival
Dana-Farber researchers have discovered ancient bacterial defenses and anti-defenses that may persist in some form in humans today and could provide insights into new approaches to cancer research and treatment.
News
What is Immunopeptidomics?
A burgeoning type of “omics” called immunopeptidomics is providing researchers with a powerful approach to discovering new ways to train a person’s immune system to fight cancer.
News
New Insights into Immunotherapy Targets for Pancreatic Cancer
Cancer research often focuses on gene mutations in the parts of the human genome that produce cellular machinery called proteins. But the rest of the genome — sometimes called the “dark genome” — can also play a role.
Document
Contraception in Patients With a History of Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of contraception in patients with a history of breast cancer.
Document
CDK4/6 Inhibitors after Progression on CDK4/6 Inhibitor in Patients With Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of CDK4/6 inhibitors after progression on CDK4/6 inhibitor in patients with hormone receptor-positive/HER2-negativ
News
Chain Reaction: The Belzutifan Journey
Countless medical innovations are born in academic laboratories.
News
Dana-Farber Research News 05.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 1 through April 15.
News
Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.
News
Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025
Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.
News
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer